ReviewTranslational lung cancer research2025
Traditional Chinese medicine in the prevention and treatment of lung cancer metastasis by regulating tumor-associated macrophages: a narrative review.
Review in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Immune-excluded and immune-suppressive tumor microenvironments: mechanisms, spatial biomarkers, and therapeutic rewiring.Frontiers in oncology · 2026Review
- Research Progress and Prospects of Saponins in the Treatment of NAFLD: A Narrative Review.Molecules (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: Lung cancer remains the leading cause of cancer-related mortality globally, with metastasis representing the principal determinant of poor clinical outcomes. Tumor-associated macrophages (TAMs), as key components of the tumor microenvironment (TME), play pivotal roles in modulating immune responses, tumor progression, and metastatic dissemination. Traditional Chinese medicine (TCM) has demonstrated potential in regulating TAM polarization, thereby inhibiting tumor metastasis. This review aims to comprehensively summarize the current evidence on how TCM modulates TAMs to prevent and treat lung cancer metastasis. Methods: We conducted a systematic search of literature on TAMs, lung cancer metastasis, and TCM published between 2016 and 2025. Following initial screening of retrieved articles, relevant sources were cross-referenced to identify additional studies. Key Content and Findings: This review presents a comprehensive summary of recent advances in the modulation of TAMs by TCM in the setting of lung cancer metastasis. TCM-derived compounds and classical herbal prescriptions have demonstrated the ability to reprogram TAMs from an immunosuppressive M2-like phenotype to an immunostimulatory M1-like phenotype. Mechanistically, these agents exert their effects by modulating multiple signaling pathways, including TLR4/NF-κB, STAT3/STAT6, PI3K/AKT, and STING/TBK1/IRF3 pathways, as well as key cytokine networks involving interleukin-6 (IL-6) and interferon-gamma (IFN-γ). Representative monomers, including curcumin, calycosin, and polyphyllin VII, as well as classical formulas such as Bu-Fei decoction (BFD) and Kejinyan decoction, exhibit anti-metastatic activity by reprogramming the immunosuppressive TME and enhancing anti-tumor immune responses. Conclusions: TCM represents a promising strategy for suppressing lung cancer metastasis by targeting TAMs and restoring immune homeostasis. Future research should focus on the standardization of TCM formulations, mechanistic elucidation, and translational validation in clinical settings. Integrating TCM with contemporary immunotherapies may yield synergistic benefits and advance precision oncology for metastatic lung cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.